What causes acute gvhd

Overview

Acute graft-versus-host disease (aGVHD) is a serious and potentially life-threatening complication that can occur after an allogeneic stem cell or bone marrow transplant. In this procedure, a patient receives healthy stem cells from a donor to replace their own diseased or damaged bone marrow. While this is often a life-saving treatment for conditions like leukemia, lymphoma, or aplastic anemia, it carries the risk of the donor's immune system (the graft) attacking the recipient's body (the host).

The fundamental cause of aGVHD lies in the immune system's inherent function: distinguishing 'self' from 'non-self'. In a successful transplant, the donor cells engraft and begin producing new blood cells for the recipient. However, if the donor's immune cells detect any differences between their own tissues and the recipient's, they can mount an immune response. This response is directed against the recipient's cells, leading to inflammation and damage in various organs. The 'graft' is the transplanted stem cells and the immune cells they contain, while the 'host' is the recipient's body.

What Exactly Triggers Acute GVHD?

The primary trigger for aGVHD is the presence of immunocompetent donor T-lymphocytes (a type of white blood cell) in the transplanted graft. These T-cells are crucial for the graft to successfully engraft and fight any residual recipient cancer cells (the graft-versus-leukemia effect). However, they can also recognize the recipient's tissues as foreign due to differences in Human Leukocyte Antigens (HLAs), which are proteins found on the surface of most cells in the body. HLAs play a vital role in the immune system's ability to differentiate between self and non-self.

Even with meticulously matched donors, minor differences in HLAs can exist. These differences can be sufficient to activate the donor T-cells, initiating the cascade of events that leads to aGVHD. The greater the HLA mismatch between the donor and the recipient, the higher the risk of developing aGVHD. This is why finding an HLA-identical sibling donor is often preferred.

The Immune System's Role in aGVHD

The immune response in aGVHD is a complex process involving several stages:

1. Effector Phase: Donor T-cells, activated by recognizing foreign HLAs on recipient cells, proliferate and migrate to target organs. They release inflammatory cytokines (signaling molecules) that recruit other immune cells and cause tissue damage.
2. Target Organs: The most commonly affected organs in aGVHD are the skin, liver, and gastrointestinal tract. This is because these tissues have a high turnover rate and are rich in cells that express HLAs, making them more visible to the donor immune system.
• Skin: Manifests as a rash, often appearing as red, itchy patches, which can progress to blistering in severe cases.
• Gastrointestinal Tract: Causes nausea, vomiting, diarrhea (which can be bloody), and abdominal pain. This can lead to malabsorption and dehydration.
• Liver: Results in elevated liver enzymes, jaundice (yellowing of the skin and eyes), and impaired liver function.
3. Cytokine Storm: The release of inflammatory cytokines contributes to a systemic inflammatory response, often referred to as a 'cytokine storm'. This can lead to widespread tissue damage, organ dysfunction, and a severe decline in the patient's overall health.

Factors Influencing the Risk of aGVHD

Several factors can influence an individual's risk of developing aGVHD:

• HLA Match: As mentioned, the degree of HLA compatibility between donor and recipient is a major determinant. Unrelated donors or donors with partial matches generally carry a higher risk compared to HLA-identical siblings.
• Donor Type: Peripheral blood stem cells (PBSCs) are more likely to cause aGVHD than bone marrow transplants, although they may offer a stronger graft-versus-leukemia effect.
• Graft Manipulation: Techniques used to process the donor graft, such as T-cell depletion (removing T-cells to reduce GVHD risk), can influence the incidence and severity. However, this can also increase the risk of graft failure and infections.
• Recipient Factors: The recipient's age, underlying disease, and immune status can also play a role.
• Conditioning Regimen: The high-dose chemotherapy or radiation therapy given before the transplant (conditioning regimen) can damage recipient tissues, potentially increasing inflammation and the subsequent risk of aGVHD.

Prevention and Management

Given the significant risks associated with aGVHD, extensive efforts are made to prevent and manage it. Strategies include:

• Donor Selection: Prioritizing HLA-matched donors.
• Immunosuppressive Therapy: Administering medications such as cyclosporine, methotrexate, tacrolimus, or mycophenolate mofetil immediately after transplant to suppress the donor's immune system and prevent it from attacking the host.
• Graft Engineering: Using techniques like T-cell depletion or infusion of regulatory T-cells to modulate the immune response.

Despite these measures, aGVHD remains a significant challenge in stem cell transplantation. Early recognition and prompt treatment are crucial for improving outcomes. Treatment typically involves escalating immunosuppressive therapy and sometimes other agents to control the immune attack.